Natural product therapy for Non-alcoholic fatty liver disease (NAFLD): Astaxanthin, isolated from heaematococcus pluvialis, and Pandalus, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 3/November/2017, 7.03 am

Natural product-based therapy for ageing-associated diseases: A therapeutic mix encompassing Lycopene, Ellagic acid & Schisandrin B (LES), isolated from Tomato, Strawberry, schisandra chinensis, increases NMN/NAD levels, decreases interaction of DBC1 with PARP1, increases PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging via down regulation of its target gene, 2/November/2017, 12.05 am
November 1, 2017
Molecular therapy for attenuating  pathogenesis associated with  Myocardial infarction: Ciglitazone, an anti-hyperglycemic drug, decreases GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, and promotes heart healing via up regulation of its target gene, 3/November/2017, 7.10 am
November 3, 2017
Show all

Significance of the study:

Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.


 

From Research findings to Therapeutic opportunity:

This study suggests, for the first time, a natural product based therapy for NAFLD. Astaxanthin, by increasing the expression of its target gene, it may (1) promote degradation of HMGCR; and (2) suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol and total cholesterol levels; (2) attenuate lipid deposition in liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, pharmacological formulations encompassing “Astaxanthin or its analogues, either alone or in combination with other drugs” may be used to treat NAFLD.

[easy_payment currency=”USD”]

Figure 1. Mechanistic insights into how Astaxanthin decreases the expression of HMGCR to prevent progression to NAFLD

 


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Astaxanthin decrease the expression of HMGCR to prevent progression of NAFLD?

Amount: $300#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org

* Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Natural product therapy for Non-alcoholic fatty liver disease (NAFLD): Astaxanthin, isolated from heaematococcus pluvialis, and Pandalus, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 3/November/2017, 7.03 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.